Our Pricing

What Is The Difference Between Wegovy And Mounjaro?

Published on: June 03, 2026

Understanding the wegovy vs mounjaro uk comparison is essential when choosing a weight loss treatment that's right for you. Both are MHRA-licensed injectable medications that have transformed weight management outcomes in clinical trials, but they work through different mechanisms and produce different results. At Cured Pharmacy, our UK-registered clinical team can assess which treatment aligns with your medical history and weight loss goals.

How Wegovy and Mounjaro Work Differently

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a single gut hormone to reduce appetite and slow gastric emptying [1]. It's been licensed in the UK since 2023 and works by activating GLP-1 receptors in the brain that regulate hunger signals.

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist available in the UK [2]. This dual-action mechanism targets two separate hormone pathways simultaneously — both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) — which research suggests produces greater metabolic effects than single-pathway treatments.

The key clinical difference lies in this dual mechanism. By activating GIP receptors alongside GLP-1 receptors, tirzepatide appears to enhance insulin sensitivity and fat metabolism more effectively than semaglutide alone, though both medications require weekly subcutaneous injection and are subject to prescriber approval based on your BMI and medical history.

Clinical Trial Results: Wegovy vs Mounjaro Efficacy

In the landmark STEP 1 trial, adults taking Wegovy achieved an average 14.9% body weight reduction over 68 weeks when combined with lifestyle interventions [1]. Participants lost an average of 15.3kg compared to 2.6kg in the placebo group, with 83.5% achieving at least 5% weight loss.

The SURMOUNT-1 trial demonstrated even greater results with Mounjaro. Participants on the highest dose (15mg) achieved an average 22.5% body weight reduction over 72 weeks — approximately 24kg average weight loss [2]. At the 10mg maintenance dose, average weight loss was 21.4%, whilst the 5mg dose produced 16% average reduction.

Head-to-head comparison data remains limited, but these separate trials suggest tirzepatide may produce greater average weight loss than semaglutide in eligible patients. However, individual responses vary significantly, and your UK prescriber will consider factors beyond efficacy alone — including your tolerance to side effects, injection preferences, and medical contraindications — when recommending treatment.

Real-World Weight Loss Expectations

Clinical trial results represent average outcomes under controlled conditions with intensive lifestyle support. In real-world UK pharmacy practice, we observe that patients who maintain consistent dosing schedules and implement dietary changes typically achieve 12-20% body weight reduction over 12-18 months, though individual results vary considerably based on adherence, starting BMI, and metabolic factors.

Dosing Schedules and Administration

Both Wegovy and Mounjaro require once-weekly subcutaneous injection, typically in the abdomen, thigh, or upper arm. The injection process is identical — both use pre-filled single-dose pens that patients self-administer at home after receiving proper training from their prescriber or pharmacist.

Wegovy follows a fixed dose escalation: starting at 0.25mg weekly, increasing every four weeks through 0.5mg, 1mg, and 1.7mg, reaching the maintenance dose of 2.4mg by week 17 [3]. This gradual titration helps minimise gastrointestinal side effects as your body adjusts to the medication.

Mounjaro offers more flexible dosing with five available strengths: 2.5mg, 5mg, 7.5mg, 10mg, and 12.5mg or 15mg [4]. Treatment begins at 2.5mg weekly for four weeks, then increases to 5mg. Your prescriber may increase the dose in 2.5mg increments every four weeks based on your response and tolerability, up to a maximum of 15mg weekly. This flexibility allows more personalised dose optimisation than Wegovy's fixed schedule.

Injection Technique and Storage

Both medications must be refrigerated between 2-8°C until first use and can be kept at room temperature (below 30°C) for up to 21 days once removed from the fridge. Rotate injection sites weekly to prevent lipodystrophy, and never inject into areas that are tender, bruised, or scarred. The entire injection takes less than 10 seconds with either pen device.

Side Effects: What to Expect with Each Treatment

Both Wegovy and Mounjaro share similar side effect profiles because they work on overlapping GLP-1 pathways. The most common adverse effects are gastrointestinal: nausea, diarrhoea, vomiting, constipation, and abdominal discomfort [1][2]. These typically occur during dose escalation and often diminish as your body adapts to the medication.

In clinical trials, approximately 44% of Wegovy patients experienced nausea, compared to 29-33% with Mounjaro at therapeutic doses [1][2]. Diarrhoea occurred in 30% of Wegovy users versus 23-27% with Mounjaro. The dual-agonist mechanism in Mounjaro may produce slightly better gastrointestinal tolerability for some patients, though individual experiences vary considerably.

Serious but rare side effects include pancreatitis, gallbladder disease, and thyroid C-cell tumours (observed in animal studies). Both medications carry a boxed warning about potential thyroid tumours and are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [3][4]. Always report persistent severe abdominal pain to your prescriber immediately.

Cost Comparison: Wegovy vs Mounjaro UK Pricing

At Cured Pharmacy, Wegovy starts from £135.00 per pen, making it one of the more accessible GLP-1 treatments available through UK online pharmacies. Mounjaro pricing starts from £124.99, reflecting its newer market entry and dual-mechanism formulation. Both prices include free clinical consultation with a UK prescriber, with final cost determined by your prescribed dose and treatment duration.

NHS availability for both medications remains limited to specialist weight management services in most regions, with strict eligibility criteria typically requiring BMI ≥35 with comorbidities or BMI ≥40. Private prescription through registered UK pharmacies like Cured Pharmacy offers faster access for eligible patients who meet clinical criteria but don't qualify for NHS provision.

When comparing total treatment costs, consider that weight loss medications require ongoing use to maintain results. Most patients remain on maintenance doses for 12-24 months or longer, so the cumulative cost difference between treatments becomes significant over time. Our transparent upfront pricing means you'll see exact costs before completing your consultation, with no hidden fees or subscription traps.

Insurance and Payment Options

Some private health insurance policies may cover weight loss medications when prescribed for obesity with comorbidities, though coverage varies significantly between providers. Check your policy documents or contact your insurer directly. Cured Pharmacy accepts all major payment methods and provides detailed receipts for insurance claims or flexible spending account reimbursement.

Which Treatment Is Right for You?

Choosing between Wegovy and Mounjaro depends on multiple clinical factors that your UK prescriber will assess during consultation. Mounjaro may be preferable if you're seeking maximum weight loss potential and can tolerate the higher cost, whilst Wegovy offers proven efficacy at a more accessible price point with slightly simpler dosing.

Your medical history plays a crucial role in treatment selection. Both medications are contraindicated in pregnancy, with personal or family history of medullary thyroid carcinoma, and in patients with severe gastrointestinal disease. If you're taking insulin or sulfonylureas, dose adjustments may be necessary to prevent hypoglycaemia when starting either treatment [3][4].

Previous experience with GLP-1 medications can inform your choice. Patients who've tried liraglutide (Saxenda) but found daily injections inconvenient often prefer weekly options like Wegovy or Mounjaro. If you've previously used Wegovy and plateaued despite good adherence, your prescriber may consider switching to Mounjaro's dual-agonist mechanism for additional weight loss, subject to clinical assessment and MHRA licensing restrictions.

Starting Your Weight Loss Journey at Cured Pharmacy

Our UK-registered clinical team, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), provides comprehensive assessment to determine your eligibility for Wegovy, Mounjaro, or alternative treatments. The online consultation takes under three minutes and covers your medical history, current medications, weight loss goals, and any contraindications. If approved, your medication is dispensed from our GPhC-registered pharmacy (9012511) and delivered in discreet packaging, typically within 24-48 hours to UK addresses.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
3. Novo Nordisk. (2023). Wegovy (semaglutide) Summary of Product Characteristics. Medicines and Healthcare products Regulatory Agency. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
4. Eli Lilly. (2023). Mounjaro (tirzepatide) Summary of Product Characteristics. Medicines and Healthcare products Regulatory Agency. https://www.medicines.org.uk/emc/product/14881 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary. Weight loss medications are most effective when combined with a reduced-calorie diet and increased physical activity.